

Innoxel is an emerging Contract Development and Manufacturing Organization (CDMO) based in India specializing in aseptic production of Injectable vials, Prefilled syringes and oral liquids. Innoxel has two separate manufacturing areas – Block-1 which handles General category products and Block-2, which will handle Potent (Oncology) category products.

Innoxel's vision is to be the partner of choice to the world's leading specialty pharmaceutical players. As a strategic development and manufacturing partner to our customers, we provide skilled support and state-of-the-art fill finish services at every step of the injectable and oral liquid product life cycle – from pre-formulation development, to exhibit and regulatory batch support to supporting commercial production, and beyond.

Innoxel was incorporated in 2020 as a green-field site and will be fully operational in August 2023. The first set of products from Innoxel will be filed with the USFDA in Q1 2024, triggering a potential USFDA inspection in early 2025. Innoxel has been designed, built and now operated to enable it to be compliant with USFDA, EUGMP and UKMHRA norms.

Innoxel is set over a manufacturing area of 350,000 sq.ft. and has annual throughputs of ~6mn oral liquid bottles/annum (100ml fill volume) and ~12mn injectable vials/annum (5ml vials). Innoxel has implemented Advanced barrier technology (isolators in the potent block and closed RABS in the general block) and software based (DMS, TMS, SAP, EQMS, LIMS, LABex, ETC.) control for all of our documentation and process engineering and is 21CFR Part 11 compliant for all manufacturing, QC and major equipments.

Innoxel has put together a team of 150+ of some of the finest manufacturing and quality professionals from across the country and is currently building out a portfolio of complex generics including liposomal injectable products which require specialized manufacturing expertise and infrastructure. Innoxel is also working on an NDA portfolio comprising of long acting forms of already approved USFDA drugs in therapeutic areas resolving several clearly established key patient compliance and adherence challenges associated with the present standard of care.